Figure 1

Impact of SARS-CoV-2 vaccination schemes on neutralization response towards the Omicron BA.1 variant. Vaccination-induced neutralization potency against Omicron (BA.1), Beta (B.1.351), Delta (B.1.617.2) or Wuhan (B.1) pseudotypes was measured in individuals who received a vector-based vaccination with single dose Ad26.CoV2.S (n = 23, a), two doses of AZD1222 (n = 25, b), two doses of mRNA vaccine BNT162b2 (n = 23, c), a heterologous two-dose vaccination with AZD1222-BNT162b2 (n = 25, d) or AZD1222-mRNA-1273 (n = 24, e), or two doses of mRNA vaccine mRNA-1273 (n = 24, f) after the indicated time periods following the last dose. FRNT₅₀ data is expressed for each serum sample, bold horizontal lines and whiskers are geometric means with 95% CI. Interconnecting lines represent sample data from the same donor. Non-neutralizing sample values were arbitrarily set to 1 for presentation purposes, indicated by a dashed line. Fold change in neutralization potency between SARS-CoV-2 B.1 and VoC pseudotypes is shown below p-values. Percentage (%) responder rates and FRNT₅₀ geometric mean titers (GMT) per SARS-CoV-2 pseudotype are shown above the individual measurements. Fold-change in neutralization potency and GMTs for SARS-CoV-2 pseudotypes are only calculated for groups where all samples had a detectable neutralizing activity, or else not applicable (na) is stated. Time between sampling and full vaccination in days is displayed as mean and SD below the vaccination scheme. Statistical analysis was performed by paired non-parametric Friedman's test followed by a Dunn's multiple comparison analysis. Statistical significance was defined by a value of * < 0.05; ** < 0.01; *** < 0.001; **** < 0.0001.